TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01773330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal manometry
Description: Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Gatorade
Description: The patient will be given Gatorade to drink at various times during the study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supine position
Description: Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-recumbent position
Description: Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sitting
Description: Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standing
Description: Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
Study: NCT01548248

Intervention type: DRUG
Intervention: insulin detemir
Description: Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.

Intervention type: DRUG
Intervention: insulin aspart
Description: Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
Study: NCT02543203

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Reconnect
Description: Topical Essential Oils mixture and aromatic method

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Reconnect
Description: Topical Essential Oils mixture and aromatic method

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Coconut oil Comparator
Description: Topical Essential Oils mixture and aromatic method

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Coconut oil Comparator
Description: Topical Essential Oils mixture and aromatic method
Study: NCT02832752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ECPR Protocol
Description: The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is \< 60 minutes, and from emergency department (ED) arrival to ECMO flows \< 30 minutes.
Study: NCT02185872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Training
Description: Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic and Resistance Training
Description: The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
Study: NCT00724191

Intervention type: PROCEDURE
Intervention: MRI
Description: New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
Study: NCT00949585

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intake of potassium
Description: Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day

Intervention type: OTHER
Group type: OTHER
Intervention: Dietary intake of potassium
Description: Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
Study: NCT04267627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)
Description: Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Assistance: Rural Interventions, Nursing, and Guidance (CARING)
Description: Cancer-related distress will be assessed using the NCCN Distress Thermometer amended to include HNC-specific areas of distress. For those participants experiencing high rates of distress, the nurse will provide targeted distress education. Education for participants exhibiting successful distress self-management, or with distress that has already resolved will focus on reinforcing surveillance and health promotion information contained in the Survivorship Care Plan. When indicated, the nurse will discuss potential referrals to support services with the patient, and they will decide jointly which referrals will be beneficial. Following the visits, the nurse will make agreed upon referrals using existing cancer center pathways, documenting these in the medical record. The nurse will follow-up with the patient via telephone 6 weeks following the telemedicine visit to determine uptake of the referral, documenting all referral information in the electronic medical record.
Study: NCT00803478

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LASIK
Study: NCT03475030

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-filled medication trays

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: automated medication reminders
Study: NCT02260830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF11167
Study: NCT01273779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talactoferrin alfa
Description: 15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
Study: NCT01453465

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03735030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human hCG 10'000 IU
Description: A single dose of 10'000 IU of human hCG will be injected in 24 healthy subject volunteers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant hCG 6'500 IU
Description: A single dose of 6'500 IU recombinant hCG will be injected in 24 healthy subject volunteers.
Study: NCT02092805

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).
Study: NCT03254771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
Study: NCT04315662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle power training with velocity loss (VL) of 10%
Description: Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 10% (VL10) in each set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle power training with velocity loss (VL) of 30%
Description: Subjects followed a muscle power training for 8 weeks (2 sessions per week on alternate days) using the leg extension exercise, with similar relative intensity (50% 1RM). Between weeks one and four two series will be performed per session. Then the number of series will increase to three per session. The inter-set recovery period will be always of 2-min. Velocity loss will be of 30% (VL30) in each set.
Study: NCT00830700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CATMH intervention
Description: This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
Study: NCT04709926

Intervention type: OTHER
Intervention: Survey
Description: Paramedics will complete a 5 minute survey that is asking for their opinions on why they did or did not take part in the PRESTO training package and also why they think paramedics might not engage with research training in general.

Intervention type: OTHER
Intervention: Interview (optional)
Description: Paramedics will also be given the option to participate in a 1hr interview to explore the questions asked in the survey in more detail.
Study: NCT03919370

Intervention type: OTHER
Intervention: No intervention
Description: there will be NO intervention

Intervention type: OTHER
Intervention: No intervention
Description: there will be NO intervention

Intervention type: OTHER
Intervention: No intervention
Description: there will be NO intervention
Study: NCT01789905

Intervention type: DRUG
Intervention: Tigecycline (Tygacil)
Description: Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study: NCT03322111

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: measurement of the cyclofusion
Description: Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
Study: NCT02287675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lymphoseek
Description: Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfur Colloid
Description: Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
Study: NCT02068105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet
Study: NCT04002518

Intervention type: DEVICE
Intervention: Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.
Description: Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.

Intervention type: DEVICE
Intervention: Biomet Cannulated Screw: 3.0, 4.0, 5.0, 6.5, and 8.0mm screws.
Description: Treatment of identified conditions, i.e. fracture fixation, arthrodesis, osteotomy, with a cannulated screw.
Study: NCT06009185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat. Zamicastat has to be taken in the morning after breakfast.
Study: NCT01947907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-001
Description: Once weekly subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Growth Hormone
Description: Once daily subcutaneous injection of human Growth Hormone
Study: NCT02866851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monitoring by Web-application
Description: Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
Study: NCT02785237

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex® ISAR Drug-eluting stent
Description: Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex® ISAR Drug-eluting stent
Description: Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultimaster® Drug-eluting stent
Description: Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultimaster® Drug-eluting stent
Description: Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
Study: NCT01633593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg PO a day, during 2 weeks
Study: NCT02068105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Sublingual tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet
Study: NCT04331665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is an inhibitor of JAK1 and JAK2 (proteins important in cell signalling) approved for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Study: NCT02575222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
Study: NCT03525860

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The subject is placed in the selected position (lying down or sitting), based on their comfort level. The areas to be needled are prepped with an alcohol swab. Mandatory standards and safety guidelines for acupuncture will be followed.~The acupuncture treatment protocol will be based on Traditional Chinese Medicine (TCM) theory. The TCM treatment strategy is designed to Benefit the Heart, Tonify Heart Qi and Blood, Calm and Sedate Cardiac Excitability and Regulate the Qi. Current literature supports the use of selected acupuncture points as possibly beneficial in regulating the autonomic nervous system, modulating Heart Rate Variability (HRV), relieving chest pain, and reducing arrhythmias.~11 sterile, single use, disposable needles will be placed one by one until all needles are in place.~Needles remain in place for additional 20 minutes or so as the patient remains in the selected position~.
Study: NCT02897375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT00868790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-3577
Description: Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
Study: NCT02897375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Given PO
Study: NCT03429725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (statements writing)
Description: Participants to write statements describing themselves or their similarities to their community.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (statements writing)
Description: Participants to write statements describing themselves or their similarities to their community.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (circling)
Description: Participants to circle either pronouns denoting themselves or pronouns denoting others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (circling)
Description: Participants to circle either pronouns denoting themselves or pronouns denoting others.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (Sumarian Warrior)
Description: Participants read a passage which described the factors that led to his success in a war.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (Sumarian Warrior)
Description: Participants read a passage which described the factors that led to his success in a war.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (all)
Description: Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online prime (all)
Description: Participants wrote statements, circled pronouns, as well as read the Sumarian Warrior passage.
Study: NCT01633593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5 mg PO a day, during 2 weeks